



Identification of Effective Genes in Feline Infectious Peritonitis and Drug Repurposing Using Systems Biology Approach

Mohammad Ahmadi Ashtiyani,^a Jalal Shayegh,^a Ali Rezapour,^b Habib MotieGhader^c

^a Department of Veterinary Medicine, Faculty of Veterinary and Agricultural Science, Shabestar Branch, Islamic Azad University, Shabestar, Iran.

^b Department of Animal Science, Faculty of Agriculture, Tabriz Branch, Islamic Azad University, Tabriz, Iran.

^c Department of Biology, Tabriz Branch, Islamic Azad University, Tabriz, Iran.

ABSTRACT

FIP is a systemic infectious disease of cats of coronavirus origin. The lack of clear signs of the presence of the virus before clinical form presentation, and the absence of easy and inexpensive diagnostic tests to confirm virus presence are among the problems for controlling and preventing the spread of the virus. In addition, there is not yet any approved medications or treatment protocols for this disease. In this paper, the gene co-expression network was first reconstructed and modulated using the STRING database and Cytoscape software. The GO and pathways of the modules were obtained using the DAVID and KEGG databases. The most important possible pathways are proteasome, protein processing in the endoplasmic reticulum, protein export, aminoacyl-tRNA biosynthesis, phagosome, tuberculosis, and T cell receptor signaling pathway. In the other part of the study, the gene-drug network regeneration strategy was used to identify a potential medicine reconstructed using the DGIdb database and Cytoscape software using the drug-gene network. BORTEZOMIB, CARFILZOMIB, OPROZOMIB, IXAZOMIB CITRATE, MARIZOMIB, BCG VACCINE, IC14, NELFINAVIR, and RITONAVIR are some of our recommended drugs for this disease. Although our computational strategy predicts repurposable candidate drugs against FIP, more detailed experimental trials and clinical analyses of drug performance, toxicity, and validation are necessary to achieve an accurate and improved treatment protocol.

Keywords

Feline infectious peritonitis, Systems biology, Gene co-expression, Drug repurposing, Coronaviridae

Number of Figures: 2
Number of Tables: 3
Number of References: 45
Number of Pages: 10

Abbreviations

BP: Biological processes
CC: Cellular components
FCoV: Feline coronavirus

FIP: Feline infectious peritonitis
FIPV: Feline infectious peritonitis virus
GO: Gene ontology

Introduction

FIP is a severe disease primarily affecting younger cats [1, 2]. Diagnosis is challenging due to the lack of definitive tests and specific symptoms [3]. It is caused by FCoV, an RNA virus belonging to the Alphacoronavirus genus with serotypes 1 and 2 [4]. Serotype 1 is more prevalent [2], but research focuses on serotype 2 due to easier laboratory propagation. FCoV can persist in dry environments for up to seven weeks and spreads indirectly [5]. Early detection of FIP is problematic as clinical signs and imaging lack specificity. Real-time polymerase chain reaction tests for viral RNA are inconclusive. Prevention outweighs treatment options due to rapid progression and diagnostic limitations [5–7]. However, efforts to develop a vaccine have been hindered by antibody-dependent enhancement [8]. Therefore, identifying effective treatments is critical.

This study employs computational biology to analyze gene expression data (dataset GSE152676) from healthy and FIP-infected cats. GO analysis using the DAVID database identifies relevant biological processes [9]. The present research aims to pinpoint FIP-related genes and potential drug targets efficiently. By leveraging a drug-gene interaction network, the study rapidly identifies candidate medications through bioinformatics and gene co-expression network analysis. This approach enhances our understanding of FIP mechanisms and aids in developing effective treatments [10].

In this study, gene expression data for FIP was obtained from the NCBI database using the GSE152676 dataset [11], which includes data from healthy and FIP-affected cats. The dataset comprises 19,493 transcripts obtained via Illumina sequencing. Significant gene expression differences ($p < 0.001$) between healthy and FIP groups were identified, resulting in 1,332 genes for network construction.

The gene co-expression network was constructed using the String database (version 11.5) [12], focusing on 1,332 genes from the previous step, specifying *Felis catus* as the species of interest. The network settings emphasized co-expression interactions with a confidence score of 0.4, excluding unconnected nodes. High-confidence data were obtained by adjusting interaction settings. The network was visualized and refined using Cytoscape software [13] and employing graph theory principles to reconstruct the main gene co-expression network (Figure 1).

Clustering

The cluster analysis of biological networks has become one of the most remarkable strategies for identifying functional modules and predicting network

biomarkers and protein complexes. The visualization of the clustering outcome is highly important for demonstrating the structure of biological networks [14]. The ClusterVis [15] plugin (version 1.0.3) was used to cluster the main network and to analyze this biological network. Cytoscape software is a powerful instrument for drawing and analyzing networks [13]. It is a platform that can be employed to run the ClusterVis plugin. In this step, the gene co-expression network data obtained from the string site were imported into the Cytoscape software version 3.8.2. Next, five performance modules were obtained using the ClusterVis plugin and the Algorithm: FAG-EC parameters and setting the algorithm parameters to DefinitionWay: Strong and OutputThreshold: 10. The list of cluster genes is provided in the supplementary file.

The GO section contains information about BP, CC, and MF. The BP refers to a biological target that comprises a gene or gene product. The procedure is performed through one or several regular sets of MFs. The CC denotes the location and structure in the cell in which the gene product is active. The MFs are defined as the biochemical activity (involving a particular binding of ligands or structures) of a gene product [16].

In this step, the list of functional cluster genes, which were obtained from the previous step, was entered into the DAVID site. Several categories of functional information were obtained after providing the requested information and selecting the species *Felis catus* as the test species. The GO and pathway sections were among the objectives of our study. In the GO section, the findings of all BP, CC, and MF categories were presented in different evaluations for each category. Moreover, we loaded and stored data for all categories and clusters to select more detailed data. All data were arranged according to the p-value and the pathways of each of the five clusters were separately loaded for reviewing and reporting purposes. The PATHWAY database is a collection of diagrams drawn manually. They are called KEGG reference pathway diagrams (maps), each of which is related to a known network of functional importance. The KEGG site was used to gain access to the pathway database [16–19].

The DGIdb is a web resource that collects and presents information on gene-drug interactions from papers, databases, and other web-based sources [20]. It lacks information on animal medications and exclusively includes human medications. Nonetheless, this study could suggest suitable drug candidates for further progressive studies. The set of all involved genes was entered into the clusters in this database. All the predicted drugs for these genes




Figure 1. Gene co-expression network for the primary gene list. In this network, there are 263 nodes (genes) and 698 edges (co-expression). Edges represent the interactions between nodes. Genes are shown in different colors according to their clusters. Cluster 1 is represented in pink, Cluster 2 in yellow, Cluster 3 in green, Cluster 4 in blue, and Cluster 5 in gray. Genes that are not assigned to any clusters are shown in light blue.

were extracted, and the medications were examined based on their effects on the involved genes and their participation in the main pathways.

GO and Pathway Enrichment Analysis:

Pathway analysis identified key pathways for each module based on p-value and gene participation:

- Module 1: Proteasome, Influenza A, Measles, Hepatitis C, and Herpes simplex infection.
- Module 2: Protein processing in the endoplasmic reticulum (26/56 genes, p-value 1.81e-34) and protein export.
- Module 3: Aminoacyl-tRNA biosynthesis.
- Module 4: Phagosome and Tuberculosis.
- Module 5: T-cell receptor signaling pathway.

Complete pathway details and participating genes are in the supplementary files.

Functional Interpretation of GO Co-expression Networks in FIP:

GO analysis using DAVID categorized information into BP, CC, and MFs for all five clusters reported with p-values < 0.

Key BPs included:

- Module 1: Response to virus, defense response, and proteolysis.
- Module 2: Intracellular protein transport and protein targeting to the membrane.
- Module 3: tRNA aminoacylation and amino acid activation.
- Module 4: Regulation of cytokine production and immune response.
- Module 5: Positive regulation of leukocyte-mediated immunity.

Detailed BP, CC, and MF data are provided in the supplementary files to manage complexity and maintain study focus.

This study employed a bioinformatics approach to unravel the genes and pathways involved in FIP, proposing repurposable drugs. Expression-modified genes from healthy and FIP-infected groups were sourced from NCBI [11]. A gene co-expression network was constructed and analyzed, revealing five gene clusters. Drugs targeting these genes were identified from the DGIdb human drug database.

Proposed Candidate Drugs

Genes from identified modules underwent analysis using the DGIdb database to pinpoint potential drugs visualized via Cytoscape (Figure 2). Notably, BORTEZOMIB and CARFILZOMIB (linked to nine genes), OPROZOMIB and IXAZOMIB CITRATE (eight genes), and MARIZOMIB (four genes) emerged as proteasome inhibitors [21–25]. Other medications with significant genetic associations included BCG VACCINE, IC14, NELFINAVIR, and RITONAVIR.

Comprehensive drug predictions are detailed in the supplementary files.

The major pathways obtained using bioinformatics databases involved proteasome, protein processing in the endoplasmic reticulum, protein export, aminoacyl-tRNA biosynthesis, phagosome, tuberculosis, and the T-cell receptor signaling pathway. The proteasome pathway, crucial for cellular regulation and quality control (p-value: 4.76E-12), emerged prominently.

Proteasome inhibitors, such as BORTEZOMIB [23], CARFILZOMIB [22], OPROZOMIB [22], IXAZOMIB CITRATE [24], and MARIZOMIB [25], originally used in cancer therapy [26], were highlighted as potential treatments for FIP. Their role in regulating key cellular proteins via the ubiquitin-proteasome system suggests antiviral potential, crucial for various stages of coronavirus infection and potentially reducing antiviral resistance [27, 28]. The study recommends these drugs as robust therapeutic options for FIP.

The tuberculosis pathway (p-value: 5.86E-04) shares similarities with FIP, involving expression-modified genes CD14, TLR4, and TLR2 [11, 29, 30], also in the Toll-like receptor signaling pathway (p-value: 0.001873) [31]. One of the drugs targeting the CD14 gene is IC14 [32], which can serve as a potential FIP treatment by inhibiting its activity, as seen in studies on SARS-CoV-2 [33].

In addition to the tuberculosis pathway, the Toll-like receptor signaling and phagosome pathways (p-value: 3.92E-07) also share common genes with tuberculosis (i.e., TLR4). The drugs suggested on the tuberculosis pathway can be effective on the two mentioned pathways.

NELFINAVIR, a protease inhibitor, showed to be promising in reducing HIV viral load and increasing CD4+ cells [34], demonstrating antiviral effects on FIP in vitro [1] and potential with *Galanthus nivalis* agglutinin for FIP [35] and SARS-CoV-2 inhibition [36].

RITONAVIR, another HIV protease inhibitor [37], was tested with LOPINAVIR for SARS-CoV-2 but did not reduce mortality [38]. GC376 [39] and GS-441524 [40] showed promise in FIP treatment, though concerns about resistance and tissue distribution remain. Effective treatments for FIP are crucial due to the toxicity of FIPV inhibitory doses and the absence of approved therapies [41, 42].

REMEDESIVIR (GS-5734), a nucleoside analog with broad antiviral activity, including FIPV [42], MERS CoV, and SARS CoV [43], has FDA approval for SARS-CoV-2 treatment [44]. XRAPHCONN®, containing GS-441524, shows promise in FIP treat-




Figure 2. Drug-Gene interaction network. Circle and hexagon nodes indicate genes and drugs, respectively.

ment but lacks widespread approval despite being easier to synthesize than REMDESIVIR [5, 45].

The development of medicines for treating FIP and other animal coronaviruses can prevent animal deaths and future virus spread. However, this study's computational approach and limited experimental resources could not validate the drugs or confirm the analyzed pathways *in vitro* and *in vivo*. Experimental validation and clinical trials are necessary to ensure

Authors' Contributions

M.A.A and H.M.G designed the study. M.A.A, J.SH and H.M.G performed the analyses. M.A.A and H.M.G reconstructed the networks. J.SH, A.R and H.M.G interpreted the results. M.A.A and H.M.G. wrote draft of the manuscript. All authors reviewed the manuscript.

Acknowledgements

No acknowledgements.

Competing Interests

The authors declare that there is no conflict of interest.

Reference

- Olsen M, Cook SE, Huang V, Pedersen N, Murphy BG. Perspectives: potential therapeutic options for SARS-CoV-2 patients based on feline infectious peritonitis strategies: central nervous system invasion and drug coverage. *Int J Antimicrob Agents*. 2020 Jun;55(6):105964. Doi: 10.1016/j.ijantimicroag.2020.105964.
- Lin L, Yao D, Wu L, Fan F, Liu Y, Zhou Z. Molecular epidemiology of type I and II feline coronavirus from cats with suspected feline infectious peritonitis in China between 2019 and 2021. *Archives of Virology* 2022; 167: 189–194. Doi: 10.3201/eid1807.120143.
- Pedersen NC. An update on feline infectious peritonitis: Virology and immunopathogenesis. *Veterinary Journal*. 2014; 201(2): 123–132. Doi: 10.1016/j.tvjl.2014.04.017.
- de Groot RJ, Baker SC, Baric R, et al. Coronaviridae - Positive Sense RNA Viruses - Positive Sense RNA Viruses (2011) - ICTV. Comité Internacional de Taxonomía de Virus (ICTV), https://talk.ictvonline.org/ictv-reports/ictv_9th_report/positive-sense-rna-viruses-2011/w/posrna_viruses/222/coronaviridae (2020, accessed 4 December 2021).
- AAddie D, Belák S, Boucraut-Baralon C, Egberink H, Frymus T, et al. Feline infectious peritonitis. ABCD guidelines on prevention and management. *J Feline Med Surg*. 2009 ;11(7):594-604. doi: 10.1016/j.jfms.2009.05.008. 6.
- Tuanthap S, Chiteafea N, Rattanasrisomporn J, Choowongkomon K. Comparative sequence analysis of the accessory and nucleocapsid genes of feline coronavirus strains isolated from cats diagnosed with effusive feline infectious peritonitis. *Arch Virol*. 2021;166(10):2779-2787. Doi: 10.1007/s00705-021-05188-7
- elten S, Hartmann K. Diagnosis of Feline Infectious Peritonitis: A Review of the Current Literature. *Viruses*. 2019 Nov 15;11(11):1068. Doi: 10.3390/v11111068.
- Takano T, Hohdatsu T, Hashida Y, Kaneko Y, Tanabe M, Koyama H. A "possible" involvement of TNF-alpha in apoptosis induction in peripheral blood lymphocytes of cats with feline infectious peritonitis. *Vet Microbiol*. 2007 Jan 31;119(2-4):121-31. Doi: 10.1016/j.vetmic.2006.08.033.
- Sherman BT, Hao M, Qiu J, Jiao X, Baseler MW, Lane HC, Imamichi T, Chang W. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). *Nucleic Acids Res*. 2022;50(W1):W216-W221. Doi: 10.1093/nar/gkac194.
- Zhang B, Horvath S. A general framework for weighted gene co-expression network analysis. *Statistical Applications in Genetics and Molecular Biology*; 4. Epub ahead of print 2005. Doi: 10.2202/1544-6115.1128.
- Malbon AJ, Russo G, Burgener C, Barker EN, Meli ML, Tasker S, Kipar A. The Effect of Natural Feline Coronavirus Infection on the Host Immune Response: A Whole-Transcriptome Analysis of the Mesenteric Lymph Nodes in Cats with and without Feline Infectious Peritonitis. *Pathogens*. 2020 Jun 29;9(7):524. Doi: 10.3390/pathogens9070524.
- Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. *Nucleic Acids Res*. 2021;49(D1):D605-D612. Doi: 10.1093/nar/gkaa1074. Erratum in: *Nucleic Acids Res*. 2021;49(18):10800. Doi: 10.1093/nar/gkab835.
- Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res*. 2003 Nov;13(11):2498-504. Doi: 10.1101/gr.1239303.
- Hao T, Peng W, Wang Q, et al. Reconstruction and application of protein-protein interaction network. *International Journal of Molecular Sciences*. 2016; 17: 907.
- Wang J, Zhong J, Chen G, Li M, Wu FX, Pan Y. ClusterViz: A Cytoscape APP for Cluster Analysis of Biological Network. *IEEE/ACM Trans Comput Biol Bioinform*. 2015 ;12(4):815-22. Doi: 10.1109/TCBB.2014.2361348.
- Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Chery JM, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. *Nat Genet*. 2000 ;25(1):25-9. Doi: 10.1038/75556

17. Kanehisa M. Toward understanding the origin and evolution of cellular organisms. *Protein Sci.* 2019;28(11):1947-1951. Doi: 10.1002/pro.3715.
18. Kanehisa M, Furumichi M, Sato Y, Ishiguro-Watanabe M, Tanabe M. KEGG: integrating viruses and cellular organisms. *Nucleic Acids Res.* 2021;49(D1):D545-D551. Doi: 10.1093/nar/gkaa970.
19. Kanehisa M, Goto S. KEGG: Kyoto Encyclopedia of Genes and Genomes. *Nucleic Acids Research* 2000; 28: 27–30.
20. Freshour SL, Kiwala S, Cotto KC, Coffman AC, McMichael JF, Song JJ, et al. Integration of the Drug-Gene Interaction Database (DGIdb 4.0) with open crowdsourcing efforts. *Nucleic Acids Res.* 2021;49(D1):D1144-D1151. Doi: 10.1093/nar/gkaa1084.
21. Hari P, Matous JV, Voorhees PM, Shain KH, Obreja M, Frye J, et al. Oprozomib in patients with newly diagnosed multiple myeloma. *Blood Cancer J.* 2019;9(9):66. Doi: 10.1038/s41408-019-0232-6.
22. Kortuem KM, Stewart AK. Carfilzomib. *Blood.* 2013;121(6):893-7. Doi: 10.1182/blood-2012-10-459883.
23. Mujtaba T, Dou QP. Advances in the understanding of mechanisms and therapeutic use of bortezomib. *Discov Med.* 2011;12(67):471-80.
24. Offidani M, Corvatta L, Caraffa P, Gentili S, Maracci L, Leoni P. An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma. *Oncol Targets Ther.* 2014;7:1793-800. Doi: 10.2147/OTT.S49187.
25. Potts BC, Albitar MX, Anderson KC, Baritaki S, Berkers C, Bonavida B, et al. Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. *Curr Cancer Drug Targets.* 2011;11(3):254-84. Doi: 10.2174/156800911794519716.
26. Adams J. The development of proteasome inhibitors as anticancer drugs. *Cancer Cell.* 2004;5(5):417-21. Doi: 10.1016/s1535-6108(04)00120-5.
27. Schneider SM, Lee BH, Nicola AV. Viral entry and the ubiquitin-proteasome system. *Cell Microbiol.* 2021;23(2):e13276. Doi: 10.1111/cmi.13276.
28. Raaben M, Posthuma CC, Verheije MH, te Lintelo EG, Kikkert M, Drijfhout JW, et al. The ubiquitin-proteasome system plays an important role during various stages of the coronavirus infection cycle. *J Virol.* 2010;84(15):7869-79. Doi: 10.1128/JVI.00485-10.
29. Bowdish DM, Sakamoto K, Kim MJ, Kroos M, Mukhopadhyay S, Leifer CA, et al. MARCO, TLR2, and CD14 are required for macrophage cytokine responses to mycobacterial trehalose dimycolate and *Mycobacterium tuberculosis*. *PLoS Pathog.* 2009;5(6):e1000474. Doi: 10.1371/journal.ppat.1000474.
30. Cubillos-Angulo JM, Fernandes CD, Araújo DN, Carmo CA, Arriaga MB, Andrade BB. The influence of single nucleotide polymorphisms of NOD2 or CD14 on the risk of *Mycobacterium tuberculosis* diseases: a systematic review. *Syst Rev.* 2021;10(1):174. Doi: 10.1186/s13643-021-01729-y.
31. Won Y, Yang JJ, Park S, Chun JS. Lipopolysaccharide Binding Protein and CD14, Cofactors of Toll-like Receptors, Are Essential for Low-Grade Inflammation-Induced Exacerbation of Cartilage Damage in Mouse Models of Posttraumatic Osteoarthritis. *Arthritis Rheumatol.* 2021;73(8):1451-1460. Doi: 10.1002/art.41679.
32. Henderson RD, Agosti JM, McCombe PA, Thorpe K, Heggie S, Heshmat S, et al. Phase 1b dose-escalation, safety, and pharmacokinetic study of IC14, a monoclonal antibody against CD14, for the treatment of amyotrophic lateral sclerosis. *Medicine (Baltimore).* 2021;100(42):e27421. Doi: 10.1097/MD.00000000000027421.
33. Messner CB, Demichev V, Wendisch D, Michalick L, White M, Freiwald A, et al. Ultra-High-Throughput Clinical Proteomics Reveals Classifiers of COVID-19 Infection. *Cell Syst.* 2020;11(1):11-24.e4. Doi: 10.1016/j.cels.2020.05.012.
34. Bardsley-Elliot A, Plosker GL. Nelfinavir: an update on its use in HIV infection. *Drugs.* 2000;59(3):581-620. Doi: 10.2165/00003495-200059030-00014.
35. Hsieh LE, Lin CN, Su BL, Jan TR, Chen CM, Wang CH, et al. Synergistic antiviral effect of *Galanthus nivalis* agglutinin and nelfinavir against feline coronavirus. *Antiviral Res.* 2010;88(1):25-30. Doi: 10.1016/j.antiviral.2010.06.010.
36. Ohashi H, Watashi K, Saso W, Shionoya K, Iwanami S, Hirokawa T, et al. Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment. *iScience.* 2021;24(4):102367. Doi: 10.1016/j.isci.2021.102367.
37. Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. *Clin Pharmacokinet.* 1998;35(4):275-91. Doi: 10.2165/00003088-199835040-00002. Erratum in: *Clin Pharmacokinet* 1998;35(6):473.
38. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. *N Engl J Med.* 2020;382(19):1787-1799. Doi: 10.1056/NEJMoa2001282.
39. Pedersen NC, Kim Y, Liu H, Galasiti Kankanamalage AC, Eckstrand C, Groutas WC, et al. Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis. *J Feline Med Surg.* 2018;20(4):378-392. Doi: 10.1177/1098612X17729626.
40. Murphy BG, Perron M, Murakami E, Bauer K, Park Y, Eckstrand C, et al. The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies. *Vet Microbiol.* 2018;219:226-233. Doi: 10.1016/j.vetmic.2018.04.026.

41. Richman DD. Antiviral drug resistance. *Antiviral Res.* 2006 ;71(2-3):117-21. Doi: 10.1016/j.antiviral.2006.03.004.
42. Delaplace M, Huet H, Gambino A, Le Poder S. Feline Coronavirus Antivirals: A Review. *Pathogens.* 2021;10(9):1150. Doi: 10.3390/pathogens10091150.
43. McFee RB. COVID-19: Therapeutics and interventions currently under consideration. *Dis Mon.* 2020;66(9):101058. Doi: 10.1016/j.disamonth.2020.101058.
44. Amirian ES, Levy JK. Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses. *One Health* 2020; 9: 100128. Doi:10.1016/j.onehlt.2020.100128.
45. Yan VC, Muller FL. Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment. *ACS Med*

COPYRIGHTS

©2024 The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers.

**How to cite this article**

Ahmadi Ashtiyani M, Shayegh J, Rezapour A, MotieGhader H. Identification of Effective Genes in Feline Infectious Peritonitis and Drug Repurposing Using Systems Biology Approach . *Iran J Vet Sci Technol.* 2024; 16(3): 99-108.
DOI: <https://doi.org/10.22067/ijvst.2024.82835.1270>
URL:https://ijvst.um.ac.ir/article_45598.html

Online supplemental material

Supplementary Excel file. The complete information of all modules separately for BP, CC, MF, and pathways, as well as gene-drug network data, are provided in this supplementary Excel file.

Visual abstract. Visual abstract of the research process

Table 1.

The details of the gene co-expression modules.

module no.	NO.	List of genes
co-expression-module-1	49	EIF2AK2, PSMD11, NMI, TXNL1, PSMB2, PSME2, PSMA6, PSMD3, PSMD4, FAM26F, CXCL11, STAT1, IFIT3, IFIT2, IRF1, UBA7, CXCL9, TRIM21, RSAD2, DHX58, CXCL10, TAP1, SAMD9L, PARP12, ISG15, STAT2, MX1, IRF7, IFI35, RTP4, LGALS3BP, OAS1, HERC6, BST2, IFI44L, HERC5, IFI44, MMS19, DTX3L, PARP9, DDX58, ZNF1, DDX60, PSMA3, UBE2L6, PSMC2, EIF2S1, IFI6, PSMB9
co-expression-module-2	56	SRPRB, TMED10, LRRC59, TRAM2, SSR3, P4HB, MANF, KDELR2, SPCS1, SEC62, SSR2, PPIC, SLC33A1, PCSK7, SSR4, DNAJC3, OS9, DAD1, HSP90B1, ERLEC1, SLC35B1, SEC61B, SDF2, HSPA5, TXNDC5, VIMP, HDLBP, DNAJB9, SEC61A1, SEC24D, PDIA5, PDIA3, SEC63, DDOST, CANX, LMAN1, TRAM1, SND1, SSR1, HM13, SIL1, SEC24A, SEC23B, COPG1, NUCB1, STT3A, CLTCL1, GMPPB, RAB5IF, PSAP, ATP1A1, PDIA6, TMED9, SPCS2, OSTC, SEC11C
co-expression-module-3	10	ASNS, MARS, HARS, AARS, WARS, EIF5A2, VARS2, GARS, NARS, LARS
co-expression-module-4	26	WAS, SASH3, TLR2, CD14, CORO1A, NCF2, TYROBP, SPI1, BLK, CTSS, SLC11A1, ADGRE1, CYBB, SLC15A3, CD80, PTAFR, FGR, C5AR1, ARHGDI1, TLR4, SRGN, MSR1, RGS18, C1orf162, ALOX5AP, C3AR1
co-expression-module-5	10	CD247, TRAF3IP3, BTN1A1, GRAP2, SH2D1A, P2RX7, GPR174, INPP5D, CD3D, ZAP70

Table 2.

The Significant Biological Pathways for all Five Clusters.

Cluster no.	PATHWAY	p-Value
co-expression-module-1	Proteasome	4.76E-12
co-expression-module-2	Influenza A	1.06E-08
co-expression-module-3	Measles	7.51E-07
co-expression-module-4	Hepatitis C	8.76E-07
co-expression-module-5	Herpes simplex infection	6.34E-06

Supplemental material Cont.

Table 3.
The candidate drugs.

Drug	NO.	Gene
BORTEZOMIB	9	PSMD11, PSMB2, PSME2, PSMA6, PSMD3, PSMD4, PSMA3, PSMC2,PSMB9
CARFILZOMIB	9	PSMD11, PSMB2, PSME2, PSMA6, PSMD3, PSMD4, PSMA3, PSMC2,PSMB9
OPROZOMIB	8	PSMD11, PSMB2, PSMA6, PSMD3, PSMD4, PSMA3, PSMC2, PSMB9
IXAZOMIB CITRATE	8	PSMD11, PSMB2, PSMA6, PSMD3, PSMD4, PSMA3, PSMC2, PSMB9
MARIZOMIB	4	PSMB2, PSMA6, PSMA3, PSMB9
RITONAVIR	2	CXCL10, TLR4
NELFINAVIR	1	TLR4
IC14	1	CD14
BCG VACCINE	1	EIF2AK2